PF-00299804 As A Single Agent, In Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Chemotherapy And Erlotinib

NCT00548093 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

66

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Non Small Cell Lung

Interventions

DRUG: PF-00299804
DRUG: PF-00299804

Sponsor

Pfizer